Royal Numico has reported a 3.2% drop in sales to €2,128m for its H1 2002. Sales in the US operations fell 8%, partially offset by a 4.7% growth in sales in Europe and 4.3% in Asia, Africa and America. Gross margins over the half year were 61.3%, slightly less than the level achieved last year. There were gross margin improvements in Infant and Enteral Clinical Nutrition, offset by a poor performance at Rexall.